吸入抗生物質の世界市場規模：製品タイプ別、用途別、流通チャネル別、地域範囲別および予測

吸入抗生物質の市場規模と予測

吸入抗生物質の市場規模は、2024年に12億8,000万米ドルと評価され、2026～2032年の予測期間中にCAGR 6.17％で成長し、2032年までに20億6,000万米ドルに達すると予測されています。

世界の吸入抗生物質市場は、喘息、慢性閉塞性肺疾患（COPD）、気管支炎、COVID-19などの慢性呼吸器疾患の罹患率の増加により、最近勢いを増しています。さらに、研究開発と企業イニシアチブの増加が吸入抗生物質の成長要因であり、予測期間における吸入抗生物質市場の成長に大きな機会を示しています。吸入抗生物質の世界市場レポートは、市場の全体的な評価を記載しています。主要セグメント、動向、市場促進要因、抑制要因、競合情勢、市場で重要な役割を果たしている要因などを包括的に分析しています。

世界の吸入抗生物質市場の定義

吸入抗生物質には、トブラマイシンとコリスチンのネブライザーとドライ粉末タイプ、ならびにネブライザーアズトレオナムが含まれます。吸入抗生物質は主に呼吸器感染症の治療に使用されます。気管支拡大症を引き起こす慢性呼吸器疾患は治療困難な感染症を伴い、治療上の大きな課題となっています。緑膿菌、メチシリン耐性黄色ブドウ球菌、バークホルデリア菌、非結核性抗酸菌などによる複合感染症は、嚢胞性線維症（CF）や非CF気管支拡大症などの慢性呼吸器疾患患者を苦しめる。

吸入抗生物質の利点は、非経口または経口の抗生物質治療に見られる全身性の副作用なしに、感染部位に高濃度の薬剤を投与できることです。ここ数十年の間に、感染症、特に根絶が困難な感染症や再発率の高い感染症の管理に役立つ吸入抗生物質の開発に対する関心が急増しています。全身療法と比較すると、吸入による抗生物質の投与は下気道感染症の治療に大きな利点があります。

世界の吸入抗生物質市場概要

慢性気道感染症は吸入抗生物質で治療されます。これらの吸入抗生物質は、標的部位に高濃度の薬剤を供給するため、他の経路よりも効果的であると考えられており、吸入抗生物質市場の成長に寄与する可能性があります。喘息、肺炎、慢性閉塞性肺疾患（COPD）、気管支炎などの呼吸器疾患の罹患率の増加は、吸入抗生物質市場全体の成長を促進すると予想されます。喘息は、世界中で数百万人が罹患する公衆衛生上の大きな問題でもあります。

慢性閉塞性肺疾患（COPD）は、早死と高い死亡率を引き起こす、生命を脅かすもう一つの肺疾患です。慢性気管支炎と肺気腫はいずれも慢性閉塞性肺疾患（COPD）の症状です。さらに、新製品開発のための研究開発活動の活発化も、吸入抗生物質市場の成長を後押しすると予想されています。吸入抗生物質は、嚢胞性線維症患者の肺感染症の治療に長い間使用されており、特に結核のような他の感染症、多剤耐性患者や広範囲に薬剤耐性を持つ患者の肺感染ルートも研究されています。

一方、薬剤の吸入に伴う副作用や、多くの病状を治療できる単一の効果的な吸入装置の難しさが、吸入抗生物質市場の成長を妨げる可能性があります。さらに、輸送施設の不規則性のために抗生物質製造のためのAPIのような原料の不十分な供給は、吸入抗生物質市場の世界の流通チャネルに影響を与える見込みです。

目次

第1章 世界の吸入抗生物質市場の導入

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 世界の吸入抗生物質市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 吸入抗生物質の世界市場：製品タイプ別

• 概要
• エアロゾル/定量吸入器
• ドライ粉末製剤
• スプレー
• その他

第6章 吸入抗生物質の世界市場：用途別

• 概要
• 肺炎
• 喘息
• 気管支炎
• その他

第7章 吸入抗生物質の世界市場：流通チャネル別

• 概要
• 病院薬局
• 小売薬局
• オンライン薬局

第8章 吸入抗生物質の世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他の欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他のアジア太平洋
• その他
  • ラテンアメリカ
  • 中東・アフリカ

第9章 世界の吸入抗生物質市場の競合情勢

• 概要
• 各社の市場ランキング
• 主要開発戦略

第10章 企業プロファイル

• Gilead Sciences
• Aradigm
• Lupin Ltd.
• Polyphor
• Insmed Incorporated
• Pharmaero
• Savara Pharmaceuticals
• Joincare Pharmaceutical Group
• Pharmaxis Ltd.
• Raptor Pharmaceutical Corp.
• Teva Canada Limited.
• Altan Pharmaceuticals.

第11章 付録

• 関連調査

Inhaled Antibiotics Market Size And Forecast

Inhaled Antibiotics Market size was valued at USD 1.28 Billion in 2024 and is projected to reach USD 2.06 Billion by 2032, growing at a CAGR of 6.17% during the forecasted period 2026 to 2032.

Global Inhaled Antibiotics Market has gained momentum in recent times because of the increasing incidence of chronic respiratory disorders such as asthma, chronic obstructive pulmonary diseases (COPD), bronchitis, and COVID-19. Furthermore, an increase in research and development and company initiatives are the factors for the growth of the inhaled antibiotics which shows significant opportunities for Inhaled Antibiotics Market growth over the forecast period. The Global Inhaled Antibiotics Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Inhaled Antibiotics Market Definition

Inhaled antibiotics include nebulized and dry powder versions of tobramycin and colistin, as well as nebulized aztreonam. Inhaled antibiotics are primarily used to treat infections of the respiratory tract. Chronic respiratory disorders that cause bronchiectasis are associated with difficult-to-treat infections, posing a significant therapeutic challenge. Complex infections caused by Pseudomonas aeruginosa, Methicillin-resistant Staphylococcus aureus, Burkholderia species, and non-tuberculous Mycobacteria can afflict patients with chronic respiratory disorders such as cystic fibrosis (CF) and non-CF bronchiectasis.

The benefits of inhaled antibiotics include the ability to deliver large concentrations of medication at the site of infection without the systemic adverse effects seen with parenteral or oral antibiotic treatments. Over the last few decades, there has been a surge in interest in the creation of inhaled antibiotics to aid in the management of infections, particularly those that are difficult to eradicate or have a high recurrence rate. When compared to systemic therapy, antibiotic delivery by inhalation has significant advantages for treating lower airway infections.

Global Inhaled Antibiotics Market Overview

Chronic respiratory airway infections are treated with inhalation antibiotics. These inhaled antibiotics are thought to be more effective than other routes since they provide a higher concentration of medications to the targeted site, which may contribute to the growth of the Inhaled Antibiotics Market. Rising incidence of respiratory diseases such as asthma, pneumonia, chronic obstructive pulmonary diseases (COPD), and bronchitis is expected to drive the growth of the overall Inhaled Antibiotics Market. Asthma is also a major public health issue that affects millions of people worldwide.

Chronic obstructive pulmonary disease (COPD) is another life-threatening lung illness that causes premature death and high mortality rates. Chronic bronchitis and emphysema are both symptoms of Chronic Obstructive Pulmonary Disease (COPD). Moreover, the increasing research and development activities for the development of novel products are also anticipated to boost the Inhaled Antibiotics Market growth. Inhaled antibiotics have long been used to treat pulmonary infections in cystic fibrosis patients, and the pulmonary route is also being explored for other infectious disorders such as tuberculosis especially, with multidrug-resistant and extensively drug-resistant patients.

Whereas side effects associated with drug inhalation and the difficulty of a single effective inhaler device that can treat many disease conditions may hamper the growth of the Inhaled Antibiotics Market. Additionally, the insufficient supply of raw materials such as APIs for antibiotics manufacturing because of irregularities in the transportation facility will affect the global distribution channel of the Inhaled Antibiotics Market.

Global Inhaled Antibiotics Market Segmentation Analysis

The Global Inhaled Antibiotics Market is Segmented into Product Type, Application, Distribution Channel, And Geography.

Inhaled Antibiotics Market, By Product Type

• Aerosol/Metered Dose Inhaler
• Dry Powder Formulation
• Spray
• Others

Based on Product Type, the market is bifurcated into Aerosol/Metered Dose Inhaler, Dry Powder Formulation, Spray, and others. The Metered Dose Inhaler segment accounted for the largest share and is anticipated to maintain its lead over the forecast period. This is attributed to its common use in the asthma and chronic obstructive pulmonary disease (COPD) drug delivery devices market.

Inhaled Antibiotics Market, By Application

• Pneumonia
• Asthma
• Bronchitis
• Others

Based on Application, the market is bifurcated into Pneumonia, Asthma, Bronchitis, and Others. The asthma segment accounts for the largest share because of genetics or environmental factors such as microbial exposure, passive smoking, and air pollution, the illness burden is increasing in both adults and children, boosting the demand for asthma treatment, which is expected to contribute to the segment's growth.

Inhaled Antibiotics Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Based on Distribution Channel, the market is bifurcated into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. The largest market segment is held by retail pharmacies owing to an increase in the popularity of online pharmacies for obtaining prescription pharmaceuticals and customers' consistent use of this distribution channel and due to an increase in the number of treatments administered through them and an increase in the number of retail pharmacies in emerging countries.

Inhaled Antibiotics Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world
• On the basis of Geography, the Global Inhaled Antibiotics Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America accounts for the largest growing segment due to an increase in the incidence of targeted diseases, an increase in the number of FDA approvals, and several product launches in the United States. Furthermore, the region's market is being driven by an increase in awareness about disease management, including prevention, diagnosis, and treatment, and an increased emphasis on respiratory illness care to improve the market in the region.

Key Players

The "Global Inhaled Antibiotics Market" study report will provide valuable insight with an emphasis on the global market including some of the major players such as Gilead Sciences, Aradigm, Lupin Ltd., Polyphor, Insmed Incorporated, Pharmaero, Savara Pharmaceuticals, Joincare Pharmaceutical Group, Pharmaxis Ltd., Raptor Pharmaceutical Corp., Teva Canada Limited, Altan Pharmaceuticals.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight to the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL INHALED ANTIBIOTICS MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL INHALED ANTIBIOTICS MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL INHALED ANTIBIOTICS MARKET, BY PRODUCT TYPE

• 5.1 Overview
• 5.2 Aerosol/Metered Dose Inhaler
• 5.3 Dry Powder Formulation
• 5.4 Spray
• 5.5 Others

6 GLOBAL INHALED ANTIBIOTICS MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Pneumonia
• 6.3 Asthma
• 6.4 Bronchitis
• 6.5 Others

7 GLOBAL INHALED ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL

• 7.1 Overview
• 7.2 Hospital Pharmacies
• 7.3 Retail Pharmacies
• 7.4 Online Pharmacies

8 GLOBAL INHALED ANTIBIOTICS MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East And Africa

9 GLOBAL INHALED ANTIBIOTICS MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Gilead Sciences
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Aradigm
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Lupin Ltd.
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Polyphor
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Insmed Incorporated
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Pharmaero
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Savara Pharmaceuticals
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Joincare Pharmaceutical Group
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Pharmaxis Ltd.
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 Raptor Pharmaceutical Corp.
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments
• 10.11Teva Canada Limited.
  • 10.11.1 Overview
  • 10.11.2 Financial Performance
  • 10.11.3 Product Outlook
  • 10.11.4 Key Developments
• 10.12 Altan Pharmaceuticals.
  • 10.12.1 Overview
  • 10.12.2 Financial Performance
  • 10.12.3 Product Outlook
  • 10.12.4 Key Developments

11 Appendix

• 11.1 Related Research